Arrowhead Pharmaceuticals' Plozasiran NDA Accepted for Familial Chylomicronemia Syndrome Treatment

Arrowhead Pharmaceuticals Advances Familial Chylomicronemia Syndrome Treatment with FDA NDA Acceptance

Arrowhead Pharmaceuticals, Inc. has made a significant stride in the development of plozasiran, an investigational therapy aimed at treating familial chylomicronemia syndrome (FCS), a rare and severe genetic disorder characterized by extremely high triglyceride levels. The U.S. Food and Drug Administration (FDA) has accepted Arrowhead's New Drug Application (NDA) for plozasiran and has designated a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025. This acceptance underscores the promising potential of plozasiran for patients suffering from FCS and related conditions, which often lead to debilitating health issues such as acute pancreatitis.

The NDA submission is bolstered by encouraging results from the Phase 3 PALISADE study, which demonstrated that plozasiran significantly reduces triglyceride levels. In the trial, participants receiving the 25 mg dosage of plozasiran experienced a remarkable median reduction in triglycerides of 80%. Moreover, the therapy also effectively lowered the risk of acute pancreatitis by 83% compared to placebo. These outcomes not only met the study’s primary endpoint but also surpassed all key secondary endpoints, highlighting plozasiran's robust efficacy profile. Dr. Chris Anzalone, Arrowhead's President and CEO, emphasizes the dedication of the team and collaborators who contributed to the successful PALISADE study, which has paved the way for further regulatory applications planned for 2025.

In addition to its promising efficacy, plozasiran has shown a favorable safety profile, with most adverse events reported being mild, including abdominal pain and nasopharyngitis. These findings were presented at major cardiovascular conferences, including the American Heart Association Scientific Sessions 2024 and the European Society of Cardiology Congress 2024. Arrowhead Pharmaceuticals is now focused on preparing for a successful launch of plozasiran, contingent on receiving FDA approval, aiming to make a substantial impact on the treatment landscape for patients with FCS and other triglyceride-related disorders.

In parallel, Arrowhead Pharmaceuticals is committed to expanding its regulatory footprint beyond the FDA, with plans to submit applications to additional regulatory authorities in 2025. This proactive approach positions the company favorably in the biopharmaceutical market, especially as it seeks to address unmet medical needs in the domain of lipid disorders. As the November PDUFA date approaches, the industry watches closely to see how plozasiran could transform treatment protocols for FCS patients and alter the management of elevated triglyceride levels.